“By integrating therapies to treat glaucoma, we strengthen our commitment to patients who need safe and reliable long-term treatments. With our global partner network, we are ready to internationalize this offering,(…) NTC can act as a comprehensive reference partner for companies entering into ophthalmology or expanding existing portfolios”, stated Riccardo Carbucicchio, CEO of NTC.

The company will highlight NT014, a fixed-dose combination eye drop developed to prevent and treat post-cataract infections, along with the Imperial line, which integrates leading technologies to enhance treatment for dry eye disease. These innovations reflect NTC’s commitment to advancing eye health through innovation, science, and strategic partnerships, setting new standards in ophthalmic care.

A partnership to support cataract surgery for children, a condition that is currently one of the leading causes of blindness in childhood in low-income countries. This is a concrete step in our commitment to the United Nations SDG 10, which promotes the reduction of inequalities. Sight is not a privilege, but a right.

A new in vitro study shows that a 2% concentration of TiAB—a compound based on silver-bound titanium dioxide—is sufficient to exert strong bactericidal activity within 24 hours against Gram-negative bacteria and support wound healing.